Real-time Estimate
Cboe BZX
10:51:29 2024-04-30 EDT
|
5-day change
|
1st Jan Change
|
2.365
USD
|
-5.40%
|
|
-15.54%
|
+39.12%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,116
|
1,923
|
930.7
|
297.2
|
255.1
|
376.6
|
-
|
-
|
Enterprise Value (EV)
1 |
2,116
|
1,923
|
930.7
|
297.2
|
255.1
|
376.6
|
376.6
|
376.6
|
P/E ratio
|
-9.4
x
|
-8.47
x
|
-4.08
x
|
-1.5
x
|
-2.13
x
|
-11.7
x
|
-39.5
x
|
13.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.5
x
|
21.7
x
|
10.8
x
|
2.76
x
|
2.01
x
|
2.6
x
|
2.15
x
|
1.77
x
|
EV / Revenue
|
14.5
x
|
21.7
x
|
10.8
x
|
2.76
x
|
2.01
x
|
2.6
x
|
2.15
x
|
1.77
x
|
EV / EBITDA
|
-
|
-8,534,465
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-16.1
x
|
-10
x
|
-4.51
x
|
-2
x
|
-
|
-11.5
x
|
-19.6
x
|
16
x
|
FCF Yield
|
-6.22%
|
-9.97%
|
-22.2%
|
-50%
|
-
|
-8.71%
|
-5.11%
|
6.25%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
90,051
|
90,855
|
101,935
|
118,888
|
150,073
|
150,637
|
-
|
-
|
Reference price
2 |
23.50
|
21.16
|
9.130
|
2.500
|
1.700
|
2.500
|
2.500
|
2.500
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-03-23
|
24-03-12
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
146
|
88.64
|
86.35
|
107.7
|
127
|
144.9
|
175.2
|
212.8
|
EBITDA
|
-
|
-225.3
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-210.7
|
-228.2
|
-217.8
|
-174.7
|
-110.6
|
-32.47
|
-9.783
|
28.7
|
Operating Margin
|
-144.34%
|
-257.41%
|
-252.27%
|
-162.21%
|
-87.07%
|
-22.41%
|
-5.59%
|
13.48%
|
Earnings before Tax (EBT)
1 |
-204.7
|
-227.3
|
-220.7
|
-182
|
-110.6
|
-32.32
|
-9.917
|
29.7
|
Net income
1 |
-204.7
|
-227.3
|
-220.7
|
-182
|
-110.6
|
-32.32
|
-9.917
|
29.7
|
Net margin
|
-140.27%
|
-256.41%
|
-255.58%
|
-169.05%
|
-87.02%
|
-22.31%
|
-5.66%
|
13.95%
|
EPS
2 |
-2.500
|
-2.500
|
-2.240
|
-1.670
|
-0.8000
|
-0.2133
|
-0.0633
|
0.1850
|
Free Cash Flow
1 |
-131.7
|
-191.6
|
-206.4
|
-148.7
|
-
|
-32.8
|
-19.25
|
23.55
|
FCF margin
|
-90.25%
|
-216.2%
|
-239.01%
|
-138.14%
|
-
|
-22.64%
|
-10.99%
|
11.06%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
79.29%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-03-23
|
24-03-12
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
23.23
|
20.66
|
23.46
|
27.63
|
26.56
|
30.03
|
29.62
|
31.76
|
31.43
|
34.23
|
32.98
|
34.52
|
36.95
|
40.48
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-51.71
|
-53.54
|
-62.92
|
-49.5
|
-41.88
|
-20.36
|
-33.06
|
-42.4
|
-24.93
|
-10.22
|
-10.87
|
-8.833
|
-7.833
|
-4.933
|
Operating Margin
|
-222.59%
|
-259.2%
|
-268.25%
|
-179.15%
|
-157.71%
|
-67.79%
|
-111.64%
|
-133.5%
|
-79.31%
|
-29.85%
|
-32.95%
|
-25.59%
|
-21.2%
|
-12.19%
|
Earnings before Tax (EBT)
1 |
-52.41
|
-54.65
|
-63.89
|
-56.36
|
-41.91
|
-19.87
|
-32.77
|
-42.06
|
-25.01
|
-10.72
|
-10.66
|
-8.745
|
-7.817
|
-5.058
|
Net income
1 |
-52.41
|
-54.65
|
-63.89
|
-56.36
|
-41.91
|
-19.87
|
-32.77
|
-42.06
|
-25.01
|
-10.72
|
-10.66
|
-8.745
|
-7.817
|
-5.058
|
Net margin
|
-225.6%
|
-264.57%
|
-272.36%
|
-203.98%
|
-157.8%
|
-66.17%
|
-110.65%
|
-132.42%
|
-79.56%
|
-31.33%
|
-32.33%
|
-25.33%
|
-21.15%
|
-12.5%
|
EPS
2 |
-0.5100
|
-0.5400
|
-0.6300
|
-0.5500
|
-0.3800
|
-0.1700
|
-0.2700
|
-0.3500
|
-0.1700
|
-0.0700
|
-0.0700
|
-0.0567
|
-0.0500
|
-0.0333
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-03
|
22-02-28
|
22-05-09
|
22-08-09
|
22-11-08
|
23-03-23
|
23-05-11
|
23-08-14
|
23-11-14
|
24-03-12
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-132
|
-192
|
-206
|
-149
|
-
|
-32.8
|
-19.3
|
23.6
|
ROE (net income / shareholders' equity)
|
-52.9%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.520
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
7.15
|
6.81
|
3.02
|
1.83
|
-
|
3
|
2.3
|
2.3
|
Capex / Sales
|
4.9%
|
7.69%
|
3.5%
|
1.69%
|
-
|
2.07%
|
1.31%
|
1.08%
|
Announcement Date
|
20-03-02
|
21-02-24
|
22-02-28
|
23-03-23
|
24-03-12
|
-
|
-
|
-
|
Average target price
6.75
USD Spread / Average Target +170.00% Consensus |
1st Jan change
|
Capi.
|
---|
| +39.12% | 377M | | +1.38% | 42.86B | | +12.43% | 42.74B | | +44.76% | 41.36B | | -8.83% | 27.68B | | +7.32% | 25.15B | | -23.14% | 18.63B | | +29.85% | 12.37B | | -2.87% | 11.92B | | +7.33% | 11.21B |
Other Biotechnology & Medical Research
|